Peregrine Capital Management LLC Increases Stake in iRhythm Technologies $IRTC

Posted by Brenda Bartman on Jul 1st, 2026

Peregrine Capital Management LLC grew its stake in shares of iRhythm Technologies (NASDAQ:IRTC – Free Report) by 15.8% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 65,875 shares of the company’s stock after purchasing an additional 9,007 shares during the quarter. Peregrine Capital Management LLC’s holdings in iRhythm Technologies were worth $7,775,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Measured Wealth Private Client Group LLC bought a new position in shares of iRhythm Technologies during the third quarter worth $30,000. GAMMA Investing LLC grew its stake in iRhythm Technologies by 48.4% during the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock valued at $33,000 after acquiring an additional 60 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in iRhythm Technologies in the 3rd quarter valued at $34,000. Employees Retirement System of Texas bought a new stake in iRhythm Technologies in the 3rd quarter valued at $36,000. Finally, Torren Management LLC purchased a new stake in iRhythm Technologies in the 4th quarter worth $53,000.

iRhythm Technologies Trading Up 0.4%

Shares of IRTC opened at $118.95 on Wednesday. The stock has a market capitalization of $3.91 billion, a PE ratio of -138.31 and a beta of 1.27. The company’s fifty day moving average is $114.95 and its 200 day moving average is $135.23. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17. iRhythm Technologies has a fifty-two week low of $100.85 and a fifty-two week high of $212.00.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.21. iRhythm Technologies had a negative net margin of 3.53% and a negative return on equity of 10.26%. The business had revenue of $199.39 million during the quarter, compared to analyst estimates of $194.11 million. During the same quarter last year, the business earned ($0.97) earnings per share. iRhythm Technologies’s quarterly revenue was up 25.6% compared to the same quarter last year. Sell-side analysts expect that iRhythm Technologies will post 0.13 earnings per share for the current fiscal year.

Insider Activity

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar bought 5,312 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $10.71 per share, for a total transaction of $56,891.52. Following the transaction, the director owned 25,611 shares of the company’s stock, valued at $274,293.81. This represents a 26.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on IRTC. The Goldman Sachs Group dropped their price objective on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen cut iRhythm Technologies from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Canaccord Genuity Group decreased their target price on iRhythm Technologies from $180.00 to $152.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Weiss Ratings raised iRhythm Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Finally, HC Wainwright reissued a “buy” rating on shares of iRhythm Technologies in a research note on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $187.38.

View Our Latest Analysis on iRhythm Technologies

iRhythm Technologies Company Profile

(Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.